EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Effect of a biomimetic pathogen adsorbing device on inflammatory biomarkers in COVID‐19 patients

Jan Schmieszek, Thomas Fuehner iD, Isabelle Renger, Tobias Welte, Jan Menne, Jan Fuge, Maria P Van't Klooster iD, Andrea Paul, Alina Siegert, Dan-Nicolae Borchina, Christine S Falk, Jan T Kielstein iD

Therapeutic Apheresis and Dialysis · 2024

DOI: 10.1111/1744-9987.14137 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Therapeutic Apheresis and Dialysis, 2024. Verfasst von Jan Schmieszek und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory, Sleep and Intensive Care Medicine, Siloah Hospital, Hannover, Germany. Hauptthemen laut MEDLINE: COVID-19, Biomarkers, Hemoperfusion, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The Seraph 100 Microbind Affinity blood filter eliminate bacteria, viruses, fungi and toxins from blood stream.

Methods

This is a prospective multicenter observational biomarker trial in PCR‐positive SARS‐CoV‐2 patients with acute respiratory failure. Biomarkers were sequentially tested at three time points.

Results

Forty‐two patients with SARS‐CoV‐2 detected by PCR with acute respiratory failure were included. When receiving hemoperfusion treatment, 27 (64%) patients were on mechanical ventilation, 41 (98%) patients were treated in the ICU. The 3‐month survival was 52%. After one hemoperfusion treatment cycle, D‐dimer ( p = 0.014), hemoglobin ( p = 0.003) and LDH ( p = 0.001) concentrations were significantly reduced 4 days after treatment. From the multiplex assay IL‐1b, CXCL8/ IL‐8, IL‐10, IL‐13, IL‐15, CCL11/Eotaxin, G‐CSF, and CXCL10/IP‐10 were significantly reduced 1 h after treatment, however not 4 days later.

Conclusion

Hemoperfusion with Seraph 100 Microbind Affinity Filter in patients with severe COVID‐19 can transiently reduce several inflammatory biomarkers in the blood.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19BiomarkersHemoperfusionSARS-CoV-2HumansMaleFemaleProspective StudiesAgedMiddle AgedFibrin Fibrinogen Degradation ProductsInflammationRespiration, Artificial

Stichwörter der Autor:innen

COVID‐19SARS‐CoV‐2biomarkerhemofiltermicrobind affinity filter

Substanzen

BiomarkersFibrin Fibrinogen Degradation Productsfibrin fragment D

Autor:innen und Institutionen

  • Department of Respiratory, Sleep and Intensive Care Medicine, Siloah Hospital, Hannover, Germany.
  • Department of Respiratory Medicine and German Centre for Lung Research (DZL/BREATH), Hannover Medical School, Hannover, Germany.
  • Department of Nephrology, Angiology, and Rheumatology, Siloah Hospital, Hannover, Germany.
  • Department of Nephrology, Rheumatology, Blood Purification, Academic Teaching Hospital Braunschweig, Braunschweig, Germany.
  • Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany.

ORCID-Profile: Thomas Fuehner, Maria P Van't Klooster, Jan T Kielstein

Zitieren

APA

Schmieszek, J., Fuehner, T., Renger, I., Welte, T., Menne, J., Fuge, J., Van't Klooster, M. P., Paul, A., Siegert, A., Borchina, D. N., Falk, C. S., & Kielstein, J. T. (2024). Effect of a biomimetic pathogen adsorbing device on inflammatory biomarkers in COVID‐19 patients. Therapeutic Apheresis and Dialysis. https://doi.org/10.1111/1744-9987.14137

Vancouver

Schmieszek J, Fuehner T, Renger I, Welte T, Menne J, Fuge J, et al. Effect of a biomimetic pathogen adsorbing device on inflammatory biomarkers in COVID‐19 patients. Therapeutic Apheresis and Dialysis. 2024. doi:10.1111/1744-9987.14137

BibTeX
@article{Schmieszek2024,
  author = {Schmieszek, Jan and Fuehner, Thomas and Renger, Isabelle and Welte, Tobias and Menne, Jan and Fuge, Jan and Van't Klooster, Maria P and Paul, Andrea and Siegert, Alina and Borchina, Dan-Nicolae and Falk, Christine S and Kielstein, Jan T},
  title = {Effect of a biomimetic pathogen adsorbing device on inflammatory biomarkers in COVID‐19 patients},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2024},
  doi = {10.1111/1744-9987.14137}
}
Kostenlos starten →